NCT04216082

A Study of Anlotinib in Subjects With Advanced Malignancy

A Single Center, Single-arm, Phase II Study of Anlotinib in Subjects With Advanced Malignancy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 93 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Anlotinib is a tyrosine kinase inhibitors (TKI) with high effective in inhibiting angiogenesis and tumor cell proliferation by targeting VEGFR, PDGFR, FGFR and c-Kit. Previous phase I trial has shown the potency of anlotinib in treating patients with various cancer types who failed in standard treatment or lack proper treatment regimen. Here, a single center, single-arm, phase II study was conducted to further validate the efficacy and safety of anlotinib in these patients.

Conditions

• Advanced Malignancy

Interventions

Type	Name	Description
DRUG	Anlotinib	Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Timeline

• Start date: 2013-08-01
• Primary completion: 2014-08-31
• Completion: 2015-08-01
• First posted: 2020-01-02
• Last updated: 2020-01-02

Locations

1 site across 1 country: China